BIOBUILD

BIOBUILD has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €74,589 and a net result of €6,889, of which €4,657 non-recurring income. Equity remains stable across the filed financial years (±0.6% per year). Its solvency ranks better than 34% of 12,678 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 1.2% (low).